Otsuka Holdings Co Ltd represents values such as innovation, creativity, and contributing to the betterment of society. As a global pharmaceutical company, they aim to improve the health and well-being of people around the world. Otsuka's corporate philosophy revolves around the concept of "Otsuka-people creating new products for better health worldwide," reflecting their commitment to developing cutting-edge medicines and healthcare solutions. With a focus on patient-centricity and social responsibility, Otsuka Holdings Co Ltd strives to address unmet medical needs and make a positive impact on society through their products and services.

Otsuka Holdings Co Ltd is primarily present in various countries and regions across the globe. The company has a significant presence in Japan, where it originated and is headquartered. In addition to its strong domestic presence, Otsuka Holdings Co Ltd has expanded its operations internationally. It has established a notable presence in the United States, Europe, and Asia, including key markets such as the United Kingdom, Germany, China, and South Korea. Through its global network, Otsuka Holdings Co Ltd aims to provide its products and services to a diverse range of customers worldwide, contributing to its growth and success as a multinational corporation.

Otsuka Holdings Co Ltd has achieved remarkable milestones throughout its history. Notably, the company experienced substantial growth, expanding its global presence and building a strong reputation in the pharmaceutical and healthcare industries. Otsuka Holdings Co Ltd successfully introduced innovative medical products and treatments, revolutionizing patient care and improving quality of life. Additionally, the company has fostered strategic partnerships, enabling the exchange of knowledge and collaboration on cutting-edge research initiatives. Otsuka Holdings Co Ltd's dedication to technological advancements, commitment to patient-centric care, and continuous efforts in medical breakthroughs have contributed to its extraordinary achievements in the industry.

Otsuka Holdings Co Ltd is a Japanese pharmaceutical company that was founded in 1964. It is headquartered in Tokyo and operates globally. Otsuka Holdings has a rich history and has been dedicated to improving the health and well-being of people worldwide. The company specializes in the research, development, and manufacturing of innovative pharmaceutical products, as well as providing comprehensive healthcare solutions. Otsuka Holdings is known for its commitment to mental health, and its flagship product, Abilify, has been widely used for the treatment of schizophrenia and bipolar disorder. With a strong emphasis on innovation and patient-centric care, Otsuka Holdings continues to make significant contributions to the healthcare industry.

The main competitors of Otsuka Holdings Co Ltd in the market are major pharmaceutical companies such as Pfizer, Novartis, and GlaxoSmithKline. These global competitors also operate within the healthcare industry and offer a wide range of products and services similar to Otsuka Holdings. Despite facing stiff competition in the market, Otsuka Holdings continues to thrive through its innovative research and development efforts, diversification of product portfolio, and strategic collaborations. Otsuka Holdings remains firmly focused on its commitment to improving the health and well-being of people through its various subsidiaries and business segments.

Otsuka Holdings Co Ltd is primarily active in the healthcare and pharmaceutical industries.

The business model of Otsuka Holdings Co Ltd focuses on healthcare, pharmaceuticals, and nutraceuticals. As a leading global company, Otsuka Holdings creates and markets innovative products and solutions to improve the overall health and well-being of individuals worldwide. Their business strategy centers around research, development, and commercialization of pharmaceuticals and medical devices that target unmet medical needs. In addition, Otsuka Holdings also offers nutritional food products and beverages. By leveraging their expertise and commitment to innovation, Otsuka Holdings aims to contribute to the advancement of healthcare and ultimately improve the quality of life for people around the globe.

Az Otsuka Holdings Co P/E mutatója 19,96.

Az Otsuka Holdings Co KUV 1,99.

Az AlleAktien Minőségi Score Otsuka Holdings Co esetében 5/10.

A várt Otsuka Holdings Co forgalma 2,24 Bio. JPY.

A(z) várt Otsuka Holdings Co nyereség 223,91 milliárd JPY.

Otsuka Holdings Co Ltd is an internationally active company that operates in various business sectors. Their business model is based on offering innovative products and services that aim to improve people's lives. The company operates in four business sectors: Pharma, Nutraceuticals, Medical Devices, and others (including Contract Manufacturing and Real Estate). In the Pharma sector, Otsuka Holdings produces and distributes pharmaceuticals for a variety of applications. These include products for the treatment of psychiatric disorders, kidney diseases, cardiovascular diseases, and other illnesses. Well-known brands include Abilify® and Samsca®. Another important business sector of Otsuka Holdings is Nutraceuticals. The company offers a wide range of nutritional supplements and functional foods based on scientific principles. Many of these products aim to improve consumers' well-being and health. Examples include Collagen C®, a new generation of beauty and anti-aging products, and Soyjoy®, a brand of energy-rich snacks based on soy. In the field of medical technology, Otsuka Holdings develops and produces a variety of medical devices to improve clinical outcomes and enhance quality of life. The focus here is on stroke treatment and hemodialysis. The products range from neurosonography to blood purification systems. In addition to these three core business sectors, Otsuka Holdings is also active in other areas. The company offers contract manufacturing services to support other companies in the production of pharmaceuticals, cosmetics, and foods. Otsuka Holdings also has a significant real estate division that focuses on property development and management investments. Overall, Otsuka Holdings is a global company that offers its customers a wide range of innovative and high-quality products and services. The company's goal is to improve people's lives worldwide and contribute to sustainable growth. To increase market presence and strengthen customer relationships, Otsuka Holdings has also entered into various distribution partnerships with other companies. Together with partners such as Bristol Myers Squibb and Takeda Pharmaceutical, the company focuses on developing new products and technologies to provide the best to customers worldwide. In summary, Otsuka Holdings Co Ltd offers a wide range of products and services in various business sectors, from Nutraceuticals to medical devices. The company strives to improve people's lives and relies on innovation and high-quality products. With strong partnerships and a global network, the company positions itself as a key player in the global healthcare industry.

A(z) Otsuka Holdings Co évente alkalommal oszt ki 100,00 JPY összegű osztalékot.

A Otsuka Holdings Co esetében jelenleg nem lehet kiszámítani a osztalékot, vagy a vállalat nem fizet osztalékot.

A(z) Otsuka Holdings Co ISIN kódja: JP3188220002.

A Otsuka Holdings Co WKN-je A1C9KC.

Az Otsuka Holdings Co tőzsdei rövidítése 4578.T.

Az elmúlt 12 hónapban a(z) Otsuka Holdings Co osztalékot fizetett 110,00 JPY összegben. Ez körülbelül 1,34 % osztalékhozamnak felel meg. A következő 12 hóban a(z) Otsuka Holdings Co várhatóan 113,93 JPY összegű osztalékot fog fizetni.

A(z) Otsuka Holdings Co jelenlegi osztalékhozama 1,34 %.

A(z) Otsuka Holdings Co negyedévente fizet osztalékot. Az osztalékokat a következő hónapokban osztják ki: július, január, július, január.

A Otsuka Holdings Co az elmúlt 16 évben minden évben fizetett osztalékot.

A következő 12 hónapban 113,93 JPY összegű osztalékra számítanak. Ez 1,38 % osztalékhozamnak felel meg.

A(z) Otsuka Holdings Co a(z) 'Egészség' szektorhoz van besorolva.

Az utolsó, Otsuka Holdings Co által 2025. 03. 01.-án/én fizetett 60 JPY összegű osztalék megszerzéséhez a részvénynek az ex-nap előtti 2024. 12. 27.-nál kellett lennie a portfóliódban.

Az utolsó osztalék kifizetése 2025. 03. 01. időpontban történt.

2023 évben a Otsuka Holdings Co 100 JPY összegű osztalékot fizetett ki.

Az Otsuka Holdings Co osztalékait JPY fizeti ki.